actin binding is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-11-13. Numbers and descriptions here follow the published literature rather than marketing material.
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
Lyophilised peptide powders are hygroscopic, and the fragment absorbs atmospheric moisture when a vial is opened at room temperature. Weighing and aliquoting are normally done quickly in a dry environment, and stock solutions are divided into single-use portions before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and can shift the measured content of a vial. These practices are general to synthetic peptides rather than unique to this sequence, but they matter more for short chains kept for long periods.
The seven-residue chain carries several polar and charged side chains, so it dissolves readily in water and in aqueous buffers near neutral pH. No cysteine is present, so disulphide formation is not a concern and reducing agents are unnecessary. Dilute ammonium hydroxide or acetonitrile-water mixtures are sometimes used for stock solutions when initial dissolution is slow. Strongly alkaline conditions and prolonged contact with oxidising agents are avoided because they can modify lysine-containing stretches, and haze in solution usually signals incomplete dissolution or aggregated material.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
| Property | Value | Notes |
|---|---|---|
| Water content | Low in freshly lyophilised material | Rises after repeated opening of the same vial |
| Solution stability | Lower than powder stability | Frozen aliquots are preferred over repeated thawing |
| Purity assessment | Reversed-phase HPLC with UV detection | Peak-area percentage excludes salts and water |
| Salt form | Often the trifluoroacetate salt | Retained from acidic purification gradients |
| Light sensitivity | Not strongly photoreactive | Dark storage still advised for long-term keeping |
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Programs are required to be accredited by SAMHSA or the Drug Enforcement Administration which is a lengthy, time- and resource-consuming process including intensive training and site visit reviews. To stay in operation, they must submit to re-accreditation every 1–3 years. Accredited programs are also able to administer buprenorphine, provided that those prescribing and administering the drug have completed the 8–24 hours of SAMHSA training. Office-based physicians who wish to prescribe buprenorphine for the treatment of opioid use disorder must also complete the required training, as well as apply for and receive a waiver from SAMHSA. Under regulation, physicians may not have more than 30 buprenorphine patients in their first year of prescribing the drug. They may apply to have this limit increased to 100 patients by year two and 275 patients by year three. In December 2015, the US Government Accountability Office began a survey of the laws and regulations around opioid treatment programs and medication-assisted treatment and found that they were barriers to getting people with opioid use disorders the treatment they need. Despite the fact that there is a shortage of opioid treatment programs across the United States, many clinicians do not want to start their own because the time and effort required to comply with the regulations is prohibitive. Individual-level barriers to accessing medication-assisted treatment also exist.
==== Types of 3D printing used in manufacturing vascularized organs ==== Extrusion Extrusion based printing is a type of printing in which material is pushed through a nozzle and extruded onto a surface or medium. While material is being extruded, either the nozzle or the print bed is moved so that the material can be placed in complex shapes across it medium. Layers upon layers of material are placed until a 3D structure is formed. The extruded material comes out as a liquid and is solidified through varies means depending on the chemical or physical properties of the material. For example, the material could be solidified through the use of photoreceptive polymerization, in which light activates the material to solidify. The material could also be hardened through the use of chemicals or enzymes. Some examples of bioinks used in extrusion based printing include some alginates, hyaluronic acid, and gellan gum.
Summit Acquisitions, LLC, a group made up of three of the company's franchisees, has assumed a strategic advisory role on behalf of the company's bondholders. Twin Peaks is no longer associated with FAT Brands and has returned to its previous status as a privately-held company. As of June 2026, the company has 115 locations, having recently opened a new lodge in Omaha, NE, with another set to open in Kissimmee, FL in late June. They also have secured signed development agreements with operators to bring Twin Peaks to Connecticut (via New London Hospitality) and another agreement that will see several new lodges in South Texas, including Brownsville, South Padre Island, and Laredo, TX.
=== Host restriction and safety for domestic animals === Currently, there is no scientific data obtained using modern detection methods that would identify SeV as an infectious - disease causing agent for humans or domestic animals. Modern methods for the identification of pathogenic microorganisms have never detected SeV in pigs or other domestic animals, despite the isolation of other paramyxoviruses. Consequently, it is recognized that Sendai virus disease causing infection is host restrictive for rodents and the virus does not cause disease in humans or domestic animals, which are natural hosts for their own parainfluenza viruses. After experimental SeV infection the virus can replicate and shed from the upper and lower respiratory tract of African green monkeys and chimpanzees, but it is not causing any disease. Sendai virus has been used and demonstrated high safety profile in clinical trials involving both adults and children to immunize against human parainfluenza virus type 1, since the two viruses share common antigenic determinants and trigger the generation of cross-reactive neutralizing antibodies. The study that was published in 2011 demonstrated that SeV neutralizing antibodies (which were formed due to human parainfluenza virus type 1 past infection) can be detected in 92.5% of human subjects worldwide with a median EC50 titer of 60.6 and values ranging from 5.9 to 11,324. Low anti-SeV antibodies background does not block the ability of SeV-base vaccine to promote antigen-specific T cell immunity.
Sources: en.wikipedia.org
With David Prokupek as CEO and Ryan focusing on developing the menu, the restaurant was designed with quick scalability in mind. The first Smashburger restaurant opened in Denver in June 2007, and the chain then expanded to Houston, and then to Minneapolis, areas where Ryan and other founding management were familiar with the local real estate market. Marketing for the restaurants focused on the customizability of the menu, freshness of ingredients, and features to give each restaurant a local feel. The chain's first marketing revolved around the tagline "Smash, sizzle, savor". In 2011, as the business was growing at a steady clip, it shifted its theme to "Smashed Fresh. Served Delicious." The restaurant identified 14 distinct customer archetypes to pursue based on income levels, geography, education and lifestyle. While it initially relied heavily on social media to build its brand, the company started television and radio advertising in 2013 with Denver-based Definite Productions as a marketing manager. It later hired one of the executives from that company as chief marketing officer. The restaurant chain grew to 143 locations, half of which are franchises, and it had $54 million in annual revenue by the end of 2011. That year, it was reported to have as many as 450 franchise agreements in the books. That year it announced plans to open new locations around airports in Kuwait, Saudi Arabia and Bahrain through franchises. It had grown to 170 locations around the world by 2013, and $228 million in revenue. In 2014 it grew to 256 locations and $300 million in revenue.
Aspergillus luchuensis (synonym Aspergillus awamori, Aspergillus inuii, Aspergillus nakazawai and Aspergillus coreanus, クロコウジキン / 黒麹菌 'kuro kōji-kin') Aspergillus niger (synonym Aspergillus batatae, Aspergillus aureus or Aspergillus foetidus, Aspergillus miyakoensis and Aspergillus usamii including A. usamii mut. shirousamii) Aspergillus tubingensis (synonym Aspergillus saitoi and A. saitoi var. kagoshimaensis) White kōji (Aspergillus kawachii) is an albino variant of Aspergillus luchuensis. It is typically used in the production of shōchū.
=== EC 2.3.2: Aminoacyltransferases === EC 2.3.2.1: D-glutamyltransferase EC 2.3.2.2: γ-glutamyltransferase EC 2.3.2.3: lysyltransferase EC 2.3.2.4: Now classified as EC 4.3.2.9, γ-glutamylcyclotransferase EC 2.3.2.5: glutaminyl-peptide cyclotransferase EC 2.3.2.6: leucyltransferase EC 2.3.2.7: aspartyltransferase EC 2.3.2.8: arginyltransferase EC 2.3.2.9: agaritine γ-glutamyltransferase EC 2.3.2.10: UDP-N-acetylmuramoylpentapeptide-lysine N6-alanyltransferase EC 2.3.2.11: alanylphosphatidylglycerol synthase EC 2.3.2.12: peptidyltransferase EC 2.3.2.13: protein-glutamine g-glutamyltransferase EC 2.3.2.14: D-alanine γ-glutamyltransferase EC 2.3.2.15: glutathione γ-glutamylcysteinyltransferase EC 2.3.2.16: lipid II:glycine glycyltransferase EC 2.3.2.17: N-acetylmuramoyl-L-alanyl-D-glutamyl-L-lysyl-(N6-glycyl)-D-alanyl-D-alanine-diphosphoundecaprenyl-N-acetylglucosamine:glycine glycyltransferase EC 2.3.2.18: N-acetylmuramoyl-L-alanyl-D-glutamyl-L-lysyl-(N6-triglycine)-D-alanyl-D-alanine-diphosphoundecaprenyl-N-acetylglucosamine:glycine glycyltransferase EC 2.3.2.19: ribostamycin:4-(γ-L-glutamylamino)-(S)-2-hydroxybutanoyl-[BtrI acyl-carrier protein] 4-(γ-L-glutamylamino)-(S)-2-hydroxybutanoate transferase EC 2.3.2.20: cyclo(L-leucyl-L-phenylalanyl) synthase EC 2.3.2.21: cyclo(L-tyrosyl-L-tyrosyl) synthase EC 2.3.2.22: cyclo(L-leucyl-L-leucyl) synthase EC 2.3.2.23: E2 ubiquitin-conjugating enzyme EC 2.3.2.24: (E3-independent) E2 ubiquitin-conjugating enzyme EC 2.3.2.25: N-terminal E2 ubiquitin-conjugating enzyme EC 2.3.2.26: HECT-type E3 ubiquitin transferase EC 2.3.2.27: RING-type E3 ubiquitin transferase EC 2.3.2.28: L-allo-isoleucyltransferase EC 2.3.2.29: aspartate/glutamate leucyltransferase EC 2.3.2.30: L-ornithine Nα-acyltransferase EC 2.3.2.31: RBR-type E3 ubiquitin transferase EC 2.3.2.32: cullin-RING-type E3 NEDD8 transferase EC 2.3.2.33: RCR-type E3 ubiquitin transferase EC 2.3.2.34: E2 NEDD8-conjugating enzyme EC 2.3.2.35: capsaicin synthase EC 2.3.2.36: RING-type E3 ubiquitin transferase (cysteine targeting)
Sources: en.wikipedia.org
==== Neurological model ==== The theoretical underpinnings of Moniz's psychosurgery were largely commensurate with the nineteenth-century ones that had informed Burckhardt's decision to excise matter from the brains of his patients. Although in his later writings, Moniz referenced both the neuron theory of Ramón y Cajal and the conditioned reflex of Ivan Pavlov, in essence he simply interpreted this new neurological research in terms of the old psychological theory of associationism. He differed significantly from Burckhardt, however in that he did not think there was any organic pathology in the brains of the mentally ill, but rather that their neural pathways were caught in fixed and destructive circuits leading to "predominant, obsessive ideas". As Moniz wrote in 1936:
Elaunin (Greek verb ἐλαύνω "I steer") is a component of elastic fibers formed from deposition of elastin between oxytalan fibers. It is found in the periodontal ligament and the connective tissue of the dermis, particularly in association with sweat glands.
=== Limitations === There are many challenges for the successful translation of mRNA into drugs because mRNA is a very large and heavy molecule(10^5 ~ 10^6 Da). Moreover, mRNA is unstable and easily degraded by nucleases, and it also activates the immune systems. Furthermore, mRNA has a high negative charge density and it reduces the permeation of mRNA across cellular membranes. Due to these reasons, without the appropriate delivery system, mRNA is degraded easily and the half-life of mRNA without a delivery system is only around 7 hours. Even though some degrees of challenges could be overcome by chemical modifications, delivery of mRNA remains an obstacle. The methods that have been researched to improve the delivery system of mRNA are using microinjection, RNA patches (mRNA loaded in a dissolving micro-needle), gene gun, protamine condensation, RNA adjuvants, and encapsulating mRNA in nanoparticles with lipids. Even though In Vitro Translated (IVT) mRNA with delivery agents showed improved resistance against degradation, it needs more studies on how to improve the efficiency of the delivery of naked mRNA in vivo.
Sources: en.wikipedia.org
Divide it into single-use aliquots and hold them frozen at -20 °C or below, protected from light. Repeated thawing of one container is the main avoidable source of variability.
Mass spectrometry confirms identity, because the measured mass is compared with the value expected from the sequence. Chromatography mainly reports how much of the material elutes as the target peak.
It usually describes the share of the chromatographic peak area recorded at a set wavelength. Salts, residual water, and solvent are excluded from that number, so it is not the same as mass fraction.
Desiccated storage at −20 °C is conventional, with −80 °C for extended periods. Vials should be warmed to room temperature before opening to prevent condensation on the powder.